CN113713067A - Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof - Google Patents
Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof Download PDFInfo
- Publication number
- CN113713067A CN113713067A CN202110982828.1A CN202110982828A CN113713067A CN 113713067 A CN113713067 A CN 113713067A CN 202110982828 A CN202110982828 A CN 202110982828A CN 113713067 A CN113713067 A CN 113713067A
- Authority
- CN
- China
- Prior art keywords
- preventing
- osteoporosis
- group
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 56
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 208000001076 sarcopenia Diseases 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title description 7
- 241000405414 Rehmannia Species 0.000 claims abstract description 13
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 13
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 13
- 239000003292 glue Substances 0.000 claims abstract description 13
- 241000208688 Eucommia Species 0.000 claims abstract description 12
- 229940107666 astragalus root Drugs 0.000 claims abstract description 12
- 241000005787 Cistanche Species 0.000 claims abstract description 10
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 10
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 10
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 10
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 241001127714 Amomum Species 0.000 claims description 3
- 235000004879 dioscorea Nutrition 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 210000000952 spleen Anatomy 0.000 abstract description 8
- 230000003213 activating effect Effects 0.000 abstract description 4
- 241000336315 Cistanche salsa Species 0.000 abstract description 3
- 210000003056 antler Anatomy 0.000 abstract description 3
- 244000141331 Amomum villosum Species 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 91
- 210000000988 bone and bone Anatomy 0.000 description 26
- 210000003205 muscle Anatomy 0.000 description 13
- 210000000689 upper leg Anatomy 0.000 description 13
- 229940011871 estrogen Drugs 0.000 description 12
- 239000000262 estrogen Substances 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 9
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 9
- 210000003414 extremity Anatomy 0.000 description 9
- 210000003194 forelimb Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 9
- 230000037396 body weight Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 206010028289 Muscle atrophy Diseases 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 230000020763 muscle atrophy Effects 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 210000001694 thigh bone Anatomy 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000001087 myotubule Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 230000025185 skeletal muscle atrophy Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 206010002027 Amyotrophy Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010046764 Uterine atrophy Diseases 0.000 description 1
- 206010048031 Wound dehiscence Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100001042 uterine atrophy Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis, which comprises the following components in percentage by mass: 10-15% of salted eucommia bark, 12-18% of wine cistanche, 5-10% of prepared rehmannia root, 12-20% of astragalus root, 12-18% of salvia miltiorrhiza, 10-15% of Chinese yam, 10-15% of fructus amomi and 7-8% of deerhorn glue. The Chinese medicinal composition for preventing and treating the sarcopenia osteoporosis can prevent and treat the osteoporosis and the muscular atrophy at the same time through the combined action of the ingredients of the salt eucommia bark, the cistanche salsa, the prepared rehmannia root, the astragalus root and the Chinese yam, the qi and the spleen tonifying, the blood enriching and the blood activating of the salvia miltiorrhiza, the spleen activating and the qi promoting of the amomum villosum, the vital essence boosting and the blood nourishing of the antler glue.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and a preparation method of the traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis.
Background
Osteoporosis (OP) is a systemic skeletal disease characterized by decreased bone mass, disrupted bone microarchitecture, and increased bone fragility, and OP and osteoporotic fractures (OPF) severely compromise human health. The castration model (OVX) is the 'gold standard' for studying postmenopausal OP at home and abroad, is also the best model for studying postmenopausal OP recommended by FDA and WHO, and is widely applied. Numerous studies have shown a complex association between osteoporosis and muscle atrophy, with the disuse OP model also showing muscle atrophy. However, can the castration model develop muscle atrophy in addition to osteoporosis? It is not clear at present. At present, OP treatment almost takes 'anti-osteoporosis treatment' as a core, but neglects osteoporosis and possibly accompanied with muscular atrophy, and can use traditional Chinese medicines to prevent and treat osteoporosis and muscular atrophy?
Based on the above, the invention provides a traditional Chinese medicine composition for preventing and treating sarcopenia, which can prevent and treat osteoporosis and muscle atrophy at the same time.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for preventing and treating sarcopenia, and solves the technical problem that the existing method for preventing and treating osteoporosis cannot prevent and treat amyotrophy simultaneously.
The second purpose of the invention is to provide a preparation method of the traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis.
The purpose of the invention is realized by the following technical scheme:
a traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis comprises the following components in percentage by mass: 10-15% of salted eucommia bark, 12-18% of wine cistanche, 5-10% of prepared rehmannia root, 12-20% of astragalus root, 12-18% of salvia miltiorrhiza, 10-15% of Chinese yam, 10-15% of fructus amomi and 7-8% of deerhorn glue.
Further, the traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis consists of the following components in percentage by mass: 12.8 percent of salted eucommia bark, 15.4 percent of wine desert cistanche, 7.7 percent of prepared rehmannia root, 15.4 percent of astragalus root, 15.4 percent of salvia miltiorrhiza, 12.8 percent of yam, 12.8 percent of amomum fruit and 7.7 percent of deerhorn glue.
Aiming at the pathogenesis of OP 'kidney deficiency, spleen deficiency and blood stasis', the eucommia ulmoides, the cistanche salsa and the prepared rehmannia root in the formula act together to tonify the kidney and strengthen the bones, the astragalus mongholicus and the Chinese yam act together to tonify qi and invigorate the spleen, and the salvia miltiorrhiza, the fructus amomi, the spleen and the qi are enlivened, the antler glue, the essence and the blood are combined to form a complete technical scheme, so that the effects of tonifying the kidney, invigorating the spleen and the blood, strengthening the bones, strengthening the muscles and relieving the pain are achieved, and the osteoporosis and the muscular atrophy can be prevented and treated simultaneously.
The preparation method of the traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis comprises the following steps:
(1) first decoction: weighing the components according to the formula ratio, adding water, soaking, boiling with strong fire, decocting with slow fire, and filtering to remove solid substances to obtain a first filtrate;
(2) and (3) second decoction: adding water into the solid filtered in the step (1), boiling with strong fire, decocting with slow fire, and filtering to remove the solid to obtain a second filtrate;
(3) mixing the first filtrate and the second filtrate, heating and concentrating to obtain the water decoction of the traditional Chinese medicine composition for preventing and treating sarcopenia and osteoporosis.
In the step (1), based on the total amount of the traditional Chinese medicine composition, 1000mL of water is added into 850g of the total amount of the traditional Chinese medicine composition according to the total mass, the soaking time is 1-2 hours, and the decocting time with small fire is 0.5-1 hour.
In the step (2), based on the total amount of the traditional Chinese medicine composition, the water is added into the decoction for 0.5 to 1 hour, wherein the water is added into the decoction according to the total mass of 850g and 750 g of water.
The concentration in the step (3) is to 750-.
Compared with the prior art, the invention has the following beneficial effects:
the Chinese medicinal composition for preventing and treating the sarcopenia osteoporosis can prevent and treat the osteoporosis and the muscular atrophy at the same time through the combined action of the ingredients of the salt eucommia bark, the cistanche salsa, the prepared rehmannia root, the astragalus root and the Chinese yam, the qi and the spleen tonifying, the blood enriching and the blood activating of the salvia miltiorrhiza, the spleen activating and the qi promoting of the amomum villosum, the vital essence boosting and the blood nourishing of the antler glue.
Drawings
FIG. 1 is a graph showing the comparison of the wet weight of uterus, liver and kidney of rats in each group tested by the present invention;
FIG. 2 is a graph showing the comparison of body composition of rats in each group tested by the present invention;
FIG. 3 is a graph showing the comparison of the weight and grip of rats in each group tested according to the present invention;
FIG. 4 is a graph showing the comparison of SMI and RSMI in various groups of rats tested according to the present invention;
FIG. 5 is a graph showing the comparison of bone density among rats in each group tested according to the present invention;
FIG. 6 is a diagram showing the micro CT comparison of femurs of rats in each group tested by the invention;
FIG. 7 is a graph showing the comparison of three-dimensional reconstruction results of rat femurs of each group tested by the present invention;
FIG. 8 is a graph showing a comparison of serological indicators for various groups of rats tested according to the present invention;
FIG. 9 is a graph showing the comparative staining of HE of femur of rats in each group tested according to the present invention (image magnification is 200 times);
FIG. 10 is a graph showing the comparison of the staining of the gastrocnemius HE of rats in each group tested according to the present invention (image magnification is 200 times).
Detailed Description
The present invention is further described below in conjunction with specific examples to better understand and implement the technical solutions of the present invention for those skilled in the art.
Example 1
A traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis comprises the following components in percentage by mass: 12.8 percent of salted eucommia bark, 15.4 percent of wine desert cistanche, 7.7 percent of prepared rehmannia root, 15.4 percent of astragalus root, 15.4 percent of salvia miltiorrhiza, 12.8 percent of yam, 12.8 percent of amomum fruit and 7.7 percent of deerhorn glue.
The preparation method of the traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis comprises the following steps:
(1) first decoction: 780g of traditional Chinese medicine decoction pieces of a traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis are added with 1000ml of water and soaked for 1 hour, the decoction is carried out for 30 minutes by small fire after the boiling by big fire, and solids are filtered to obtain a first filtrate.
(2) Second decoction: adding 800ml of water, boiling with strong fire, decocting with slow fire for 30 minutes, and filtering to obtain a solid substance to obtain a second filtrate.
(3) Mixing the first filtrate and the second filtrate, heating and concentrating to 780ml, containing crude drug 1g/ml, and administering dosage of 20g/60kg × 6.25 ═ 2.083 g/kg/d.
Example 2
A traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis comprises the following components in percentage by mass: 10% of salted eucommia bark, 18% of wine-processed cistanche, 5% of prepared rehmannia root, 12% of astragalus root, 18% of salvia miltiorrhiza, 15% of Chinese yam, 15% of fructus amomi and 7% of deerhorn glue.
Example 3
A traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis comprises the following components in percentage by mass: 15% of salted eucommia bark, 12% of wine-processed cistanche, 10% of prepared rehmannia root, 20% of astragalus root, 15% of salvia miltiorrhiza, 10% of Chinese yam, 10% of fructus amomi and 8% of deerhorn glue.
Example 4
A traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis comprises the following components in percentage by mass: 12% of salted eucommia bark, 16% of wine-processed cistanche, 7% of prepared rehmannia root, 14% of astragalus root, 18% of salvia miltiorrhiza, 12% of Chinese yam, 14% of fructus amomi and 7% of deerhorn glue.
Example 5
A traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis comprises the following components in percentage by mass: 14% of salted eucommia bark, 13% of wine-processed cistanche, 9% of prepared rehmannia root, 16% of astragalus root, 15% of salvia miltiorrhiza, 13% of Chinese yam, 12% of fructus amomi and 8% of deerhorn glue.
Test of
1 Material
1.1 animals
SPF-grade female non-pregnant 6-month-old SD rats 60 were purchased from the Experimental animal center of Chinese medicine university, Guangzhou, under the certification code SCXK (Guangdong) 2018-. The experiment is carried out in SPF laboratory of laboratory animal center of Guangzhou university of traditional Chinese medicine, and the rats are fed with special common feed and sterile water. The experiment was carried out with approval from the ethical committee of laboratory animals of the university of traditional Chinese medicine in Guangzhou (approval No. 20190429001).
1.2 drugs and reagents
The Chinese medicinal compound decoction is provided by yellow soldier pharmacist of pharmacy of third subsidiary hospital of Guangzhou Chinese medicinal university. All the Chinese medicinal materials are purchased from Lingnan Chinese medicinal decoction pieces Limited company, and are qualified by the inspection and verification of finished products. The traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis comprises the following components: example 1 was prepared. Estradiol valerate tablets (Bayer medicine health products, Guangzhou division, national standard J20171038; specification 1 mg). The administration dose of the traditional Chinese medicine composition for preventing and treating the sarcopenia osteoporosis is 2.083g/kg/d and the administration dose of the estradiol tablet is 0.104mg/kg/d according to the conversion of the body surface area of a human and a rat. 500ml of 0.9% sodium chloride injection (Guangxi Yuyuan pharmaceutical Co., Ltd., national Standard H19010205), sodium penicillin for injection (Shandong Lu anti-medicine Co., Ltd., national Standard H37020080), 4% paraformaldehyde (biosharp), absolute ethyl alcohol, xylene, novel decalcification solution (Solarbio), hematoxylin staining solution, eosin staining solution and the like.
1.3 instruments
Analytical balance (sartorius, germany); YLS-13A rat and rat grip tester (Jinan Yiyan science and technology development Co., Ltd.); discovery type a dual-energy X-ray bone densitometer (Hologic, usa); micro CT (Scanco Medical); a dehydrator; an embedding machine; a pathological microtome; freezing; a tissue sheet spreader; an oven; upright optical microscope (Nikon).
2 method
2.1 animal grouping, modeling and administration
The experiment of 60 SPF female rats is adapted to the environment for 1 week before the beginning, and after 1 week, the experiment is randomly divided into a normal group (Control), a Sham operation group (Sham), a castration group (OVX), a traditional Chinese medicine composition group (OVX + JGN) for castration and prevention and treatment of sarcopenia and osteoporosis and a castration + E by using a Rand function according to the body weight2Group (OVX + E)2). OVX group, OVX + JGN group and OVX + E group2The group was bilateral ovaries excised by rat dorsal approach bilateral ovariectomy, the Sham group was dissected by rat dorsal approach isometric adipose tissue near ovaries, and muscles and skin were sutured layer by layer. Except for the Control group, rats in each group were injected with 8 ten thousand units of penicillin sodium per muscle 1 time a day for 3 consecutive days. After 3 months of molding, the medicine is driedAnd (4) pre-treating. The Control group, the Sham group and the OVX group are filled with 10ml/kg normal saline every day, the OVX + JGN group is filled with 2.083g/kg traditional Chinese medicine decoction every day, and the OVX + E group2The group was gavaged daily at 0.104mg/kg estradiol for 3 months.
2.2 weight and grip detection
Rat body weight and forelimb grasping power were measured before model building (T0), before drug administration (T1) and before material drawing (T2), respectively. Rat Forelimb grip (Forelimb grip) was measured periodically weekly using a YLS-13A rat grapple machine. Before the test, the rat is adaptive for 10 minutes on a gripping instrument, then the rat tail is quickly gripped, after the fore limb of the rat is firmly gripped and the hind limb is suspended, the rat is slightly pulled backwards horizontally, the maximum gripping force reading is recorded for 3 times, and the average value of the three times of gripping force is used as an index for reflecting the muscle strength of the fore limb.
2.3 taking materials and detecting wet weight
Before taking the materials, rats were anesthetized. Collecting blood from abdominal aorta, separating serum, and freezing at ultralow temperature. Completely separating left femur, left gastrocnemius, left soleus, uterus, liver and kidney, removing clean peripheral soft tissue, rinsing with precooled PBS, removing surface water with absorbent paper, and weighing wet weights of uterus (ZM), liver (GM) and kidney (SM) with an analytical balance. After weighing, the mixture is placed in a 10ml centrifuge tube and fixed by paraformaldehyde.
2.4 Dual energy X-ray bone Densitometer (DXA) detection
Before material drawing, rats are anesthetized, and the whole body bone density (BMD), femur BMD, lean mass, fat mass, bone mineral mass, limb lean mass and the like of the rats are respectively measured by using the whole body of the rats and the regional high resolution in the DXA small animal mode. The percent total bone mineral content (total bone mineral content/body weight, BMC) and percent FAT content (total FAT content/body weight, FAT) were calculated for the rats. Criteria made from multiple sarcopenia work groups[11-14]The rat skeletal muscle mass index (total skeletal muscle mass/body weight, SMI) and the limb skeletal muscle mass index (limb skeletal muscle mass/body weight, RSMI) were calculated.
2.5micro CT detection
And carrying out micro CT scanning on the isolated left femur. Selecting cancellous bone by taking cancellous bone from a frame with analysis software (CTAn) of an instrumentCancellous Bone 1mm above the distal femoral growth plate was used as the region of interest, and Bone volume fraction (BV/TV,%), Bone surface density (BS/TV, mm) were analyzed-1) Trabecular Thickness (tb. th, mm), Trabecular Number (tb. n, mm)-1) And Trabecular Separation, tb.sp, mm, and reconstructing a three-dimensional image of the distal femur by instrumental self-contained analysis software (CTvox).
2.6 serological testing of rats
According to the description of ELISA kit, rat serum AKP, PINP, beta-CTx, IGF-1 and E are detected by ELISA method2And (4) content.
2.7 pathological staining
Respectively making paraffin sections of the left femur and gastrocnemius, and then sequentially performing paraffin section dewaxing, hematoxylin staining of cell nucleus, eosin staining of cytoplasm, dehydration and mounting, microscopic examination and image acquisition and analysis.
2.8 statistical analysis
The data analysis is carried out by adopting SPSS20.0 statistical analysis software, and the average +/-standard deviation of the measured data is adopted
And (4) showing. Weight and forelimb grip analysis measured periodically weekly the statistical method chosen for repeated measures analysis of continuous numerical variables was repeated measures analysis of variance in a general linear model. Single factor analysis of variance was used for comparisons among other groups, and all data were first tested for normality and homogeneity of variance. If the variance is uniform, the LSD method is adopted for the comparison between groups. If the variance is not uniform, a Welch (W) correction test is performed, followed by Dunnett’s T3 (3). With P<0.05 judged that the difference was statistically significant.
3 results
3.1 general conditions in groups of rats
During the experiment, 1 rat in Sham group died due to wound dehiscence after operation, 2 rats in OVX + JGN group died due to stomach filling and aspiration, and the number of animals finally included in the study was 57.
3.2 Wet weight detection of uterus, liver and kidney in various groups of rats
The wet weight of the uterus, the liver and the kidney of each group of rats are detected, and the OVX group, the OVX + JGN group and the OVX + E group are detected2The wet weight of the uterus of the rats in the group is obviously reduced compared with that of the Control group and the Sham group, and the wet weight of the liver and the kidney of each group is not different, so that the situation that the castration obviously causes the uterine atrophy of the rats, the liver and the kidney are not influenced, and the model construction is successful. See figure 1 for specific results. In contrast to the Control group,ap is less than 0.05; in contrast to the Sham group,bp is less than 0.05; compared with the OVX group, the method has the advantages that,cp is less than 0.05; in comparison with the OVX + JGN group,dp is less than 0.05, the same applies below.
3.3 analysis of body composition of rats in each group
Compared with the Control group and the Sham group, the BMC and FAT of the OVX group rats were significantly decreased, indicating that castration caused a decrease in bone mineral content and an increase in FAT content in the rats. Compared with the OVX group, the traditional Chinese medicine composition for preventing and treating the sarcopenia and the estrogen obviously increase the bone mineral content of the castrated rats and reduce the fat content, which indicates that the traditional Chinese medicine composition for preventing and treating the sarcopenia and the estrogen can increase the bone mineral content of the castrated rats, reduce the fat content and adjust the body composition change of the rats. The body weights of the rats in each group were not statistically different, and the results are shown in FIG. 2.
3.4 weight and grip of rats in each group
The weight and forelimb holding power of the rats in each group are measured before model building (T0), before drug administration (T1) and before material taking (T2), and the weights of the rats in each group are not statistically different. At T0, there was no statistical difference in forelimb gripping force among the groups; at T2, OVX + JGN group and OVX + E2The front limb holding power of the group is increased compared with that of the OVX group, but the difference is not statistically significant, which indicates that the Chinese medicinal composition for preventing and treating sarcopenia and estrogen can increase the front limb holding power of the castrated rats. Specific results referring to fig. 3, note: (A) continuously comparing the body weights of rats in each group before model building (T0), before medicine taking (T1) and before material taking (T2); (B) continuously comparing the front limb holding power of rats in each group before model building (T0), before medicine taking (T1) and before material taking (T2); (C) the forelimb grasping power of the rats in each group was compared at time points T0 and T2 in a cross section.
3.5 skeletal muscle Mass index and Limb skeletal muscle Mass index in rats in each group
In the OVX group rats, SMI and RSMI were significantly reduced compared to Sham, indicating that castration resulted in skeletal muscle atrophy in rats. OVX + JGN group and OVX + E compared to OVX group2The SMI and RSMI of the group rats are obviously increased, which shows that the traditional Chinese medicine composition for preventing and treating sarcopenia and the estrogen for preventing and treating the skeletal muscle atrophy of the rats caused by castration. Specific results see fig. 4, note: (A) regions of interest for the four limbs of each group of rats; (B) SMI comparison of rats in each group; (C) rats in each group were compared for RSMI.
3.6 bone Density in groups of rats
In contrast to the Control and Sham groups, OVX rats had significantly decreased systemic and femoral BMD, indicating that the castrated rats developed osteoporosis. OVX + JGN and OVX + E compared to OVX2The BMD of the whole body and the BMD of the thighbone of the group rats are obviously increased, which shows that the traditional Chinese medicine composition for preventing and treating sarcopenia and the estrogen can both prevent and treat the osteoporosis caused by castration. See figure 5 for specific results.
3.7 micro CT of thighbone of rats in each group
Compared with the Control group and the Sham group, BV/TV, BS/BV, BS/TV, Tb.Th and Tb.N of the thighbone of the rats in the OVX group are obviously reduced, Tb.Sp is obviously increased, which shows that the trabecular bone at the far end of the thighbone is sparse, the volume is reduced, the number and the thickness of the trabecular bone are obviously reduced, the separation degree of the trabecular bone is obviously increased, and the osteoporosis occurs at the far end of the thighbone. OVX + JGN group and OVX + E compared to OVX group2BV/TV, BS/BV, BS/TV, Tb.Th and Tb.N of femurs of rats are obviously increased, Tb.Sp is obviously reduced, which shows that the traditional Chinese medicine composition for preventing and treating sarcopenia and the estrogen obviously increase the volume, the number and the thickness of trabeculae, reduce the separation degree of the trabeculae and prevent and treat OP. This is consistent with the results of the three-dimensional reconstruction of the distal femur. See fig. 6 and 7 for specific results.
3.8 serological assay in rats
Compared with Control group and Sham group, OVX group rats serum bone formation markers AKP, IGF-1 and E2The level is obviously reduced, and the level of a bone resorption marker beta-CTx is obviously increased, which indicates that castration inhibits the bone formation of rats and promotes the bone resorption. OVX + JGN group and OVX + E compared to OVX group2Serum bone formation marker for group ratsSubstances AKP, IGF-1 and E2The level is obviously increased, and the level of a bone resorption marker beta-CTx is obviously reduced, which shows that the traditional Chinese medicine composition for preventing and treating sarcopenia and the estrogen inhibit the bone resorption of the castrated rats, promote the bone formation and prevent and treat the osteoporosis of the castrated rats. See figure 8 for specific results.
3.9 pathological staining of gastrocnemius and femur in rats of each group
3.9.1 femoral HE staining
Compared with Control group and Sham group, the OVX group rats had significantly reduced trabecular bone number, decreased thickness, interrupted continuity, increased resolution, and severe bone marrow adipogenesis. OVX + JGN group and OVX + E compared to OVX group2The number of the thighbone trabeculae of the rats is obviously increased, the thickness is increased, the separation degree is reduced, and the bone marrow adiposity is reduced, which shows that the traditional Chinese medicine composition for preventing and treating sarcopenia and osteoporosis and the estrogen can both prevent and treat osteoporosis. See figure 9 for specific results.
3.9.2 gastrocnemius HE staining
Compared with Control group and Sham group, rats in OVX group had disorganized gastrocnemius muscle fiber arrangement, increased muscle space, muscle fiber atrophy, and decreased muscle nucleus shrinkage. OVX + JGN group and OVX + E compared to OVX group2The rats in the group have tightly arranged gastrocnemius muscle fibers, reduced muscle gaps, thickened muscle fibers and increased muscle cell nucleus, and the traditional Chinese medicine composition for preventing and treating sarcopenia and osteoporosis and the estrogen can prevent and treat the muscular atrophy. See figure 10 for specific results.
The invention researches the influence of castration on the bones and muscles of the rat by constructing a rat castration model. Research shows that compared with the Control group and the Sham group, the OVX group rats have obviously reduced systemic BMD and femoral BMD, sparse distal femoral trabecula, reduced number, reduced thickness, increased separation degree, increased bone marrow adiposity, reduced serum bone formation markers and increased bone absorption markers, and indicate that the OVX rats have osteoporosis. In addition to osteoporosis, OVX rats also developed significant skeletal muscle atrophy. Compared with the Control group and the Sham group, the rats in the OVX group have obviously reduced SMI and RSMI, disorganized gastrocnemius muscle fiber arrangement, hyperplasia of connective tissue between muscle fibers, obviously shrunken muscle nucleus and serious muscle adiposity, which indicates that the rats in the OVX group have muscle atrophy. It can be seen that castration causes not only osteoporosis but also atrophy of the rat muscle.
The invention intervenes an OVX rat model by using the traditional Chinese medicine composition for preventing and treating sarcopenia to clearly prevent and treat osteoporosis and amyotrophy. Research shows that compared with the OVX group, the OVX + JGN group and OVX + E2 group rats have obviously improved whole body BMD and femur BMD, increased number of bone trabeculae at the distal end of femur, increased thickness, reduced separation degree, reduced bone marrow adiposity, increased serum bone formation markers, reduced bone absorption markers, and the traditional Chinese medicine composition for preventing and treating sarcopenia and the estrogen for preventing and treating the osteoporosis of the castrated rats. In addition to preventing and treating osteoporosis, the traditional Chinese medicine composition for preventing and treating sarcopenia and the estrogen can also prevent and treat muscular atrophy. Compared with the OVX group, the anterior limb holding power of rats in the OVX + JGN group and the OVX + E2 group tends to be increased, SMI and RSMI are obviously increased, gastrocnemius muscle fibers are closely arranged, the connective tissues between the muscle fibers are reduced, muscle cores are obviously enlarged, and muscle adiposity is reduced, which indicates that the traditional Chinese medicine composition for preventing and treating sarcopenia and the estrogen can both prevent and treat the muscle atrophy.
The above embodiments illustrate various embodiments of the present invention in detail, but the embodiments of the present invention are not limited thereto, and those skilled in the art can achieve the objectives of the present invention based on the disclosure of the present invention, and any modifications and variations based on the concept of the present invention fall within the scope of the present invention, which is defined by the claims.
Claims (6)
1. A traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis is characterized by comprising the following components in percentage by mass: 10-15% of salted eucommia bark, 12-18% of wine cistanche, 5-10% of prepared rehmannia root, 12-20% of astragalus root, 12-18% of salvia miltiorrhiza, 10-15% of Chinese yam, 10-15% of fructus amomi and 7-8% of deerhorn glue.
2. The traditional Chinese medicine composition for preventing and treating sarcopenia according to the claim 1 is characterized by comprising the following components in percentage by mass: 12.8 percent of salted eucommia bark, 15.4 percent of wine desert cistanche, 7.7 percent of prepared rehmannia root, 15.4 percent of astragalus root, 15.4 percent of salvia miltiorrhiza, 12.8 percent of yam, 12.8 percent of amomum fruit and 7.7 percent of deerhorn glue.
3. A method for preparing the traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis as claimed in claim 1 or 2, which is characterized by comprising the following steps:
(1) first decoction: weighing the components according to the formula ratio, adding water, soaking, boiling with strong fire, decocting with slow fire, and filtering to remove solid substances to obtain a first filtrate;
(2) and (3) second decoction: adding water into the solid filtered in the step (1), boiling with strong fire, decocting with slow fire, and filtering to remove the solid to obtain a second filtrate;
(3) mixing the first filtrate and the second filtrate, heating and concentrating to obtain the water decoction of the traditional Chinese medicine composition for preventing and treating sarcopenia and osteoporosis.
4. The method as claimed in claim 3, wherein the amount of water added in step (1) is 1000mL per 850g of total mass of the Chinese medicinal composition, the soaking time is 1-2 hours, and the decocting time with slow fire is 0.5-1 hour.
5. The method as claimed in claim 4, wherein the amount of water added in step (2) is 800mL per 850g of total mass of the Chinese medicinal composition, and the decoction time is 0.5-1 hr with slow fire.
6. The method for preparing a Chinese medicinal composition for preventing and treating sarcopenia as claimed in claim 5, wherein the concentration in step (3) is 750-850 mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110982828.1A CN113713067B (en) | 2021-08-25 | 2021-08-25 | Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110982828.1A CN113713067B (en) | 2021-08-25 | 2021-08-25 | Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113713067A true CN113713067A (en) | 2021-11-30 |
| CN113713067B CN113713067B (en) | 2023-03-10 |
Family
ID=78677943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110982828.1A Active CN113713067B (en) | 2021-08-25 | 2021-08-25 | Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113713067B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115414409A (en) * | 2022-08-19 | 2022-12-02 | 北京中医药大学 | Medicine for treating sarcopenia-osteoporosis |
| CN116763884A (en) * | 2023-07-31 | 2023-09-19 | 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广东省中医骨伤研究院) | Traditional Chinese medicine mixture for treating sarcopenia-osteoporosis and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988607A (en) * | 2012-11-24 | 2013-03-27 | 王萍 | Health-care traditional Chinese medicine composition for osteoporosis |
| CN104352718A (en) * | 2014-11-26 | 2015-02-18 | 湖南中医药大学 | Medicine for treating osteoporosis and preparation method thereof |
-
2021
- 2021-08-25 CN CN202110982828.1A patent/CN113713067B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988607A (en) * | 2012-11-24 | 2013-03-27 | 王萍 | Health-care traditional Chinese medicine composition for osteoporosis |
| CN104352718A (en) * | 2014-11-26 | 2015-02-18 | 湖南中医药大学 | Medicine for treating osteoporosis and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 吴永威等: "健骨散治疗绝经后妇女骨质疏松症76例", 《中医药信息》 * |
| 杨先文等: "补肾健脾活血方对大鼠悬尾试验性骨质疏松和肌萎缩影响的实验研究", 《山西中医药大学学报》 * |
| 秦大平等: "从筋骨并重理论探讨肌少症与骨质疏松症的中医药防治策略", 《中华中医药杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115414409A (en) * | 2022-08-19 | 2022-12-02 | 北京中医药大学 | Medicine for treating sarcopenia-osteoporosis |
| CN116763884A (en) * | 2023-07-31 | 2023-09-19 | 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广东省中医骨伤研究院) | Traditional Chinese medicine mixture for treating sarcopenia-osteoporosis and preparation method thereof |
| CN116763884B (en) * | 2023-07-31 | 2024-01-23 | 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广东省中医骨伤研究院) | Traditional Chinese medicine mixture for treating sarcopenia-osteoporosis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113713067B (en) | 2023-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113713067B (en) | Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof | |
| Sun et al. | Total flavonoids of rhizoma drynariae ameliorates bone formation and mineralization in BMP-Smad signaling pathway induced large tibial defect rats | |
| CN101966222A (en) | Medicinal composition and preparation for strengthening bones and preparation method thereof | |
| US7081259B2 (en) | Herbal, extract having therapeutic activity on injuries, and pharmaceutical composition and health food containing the same | |
| CN103721242A (en) | New application of pharmaceutical composition in prevention or treatment of osteoporosis | |
| CN107892725B (en) | Rhizoma curculiginis polysaccharide and preparation method and application thereof | |
| CN107349333B (en) | Composition with effect of increasing bone mineral density and preparation method and application thereof | |
| CN107184645A (en) | It is a kind of to treat compound Chinese medicinal preparation of osteoporotic fracture and its production and use | |
| CN106334001A (en) | Application of cistanche phenylethanoid glycosides effective part in preparation of bone formation accelerating drug and drug composition | |
| CN107890475B (en) | Preparation method of epimedium extract and prepared extract | |
| CN111588763B (en) | Thrombus dredging medicine, preparation method and content determination method | |
| CN1322872C (en) | Fracture union-promoting medicine and its preparation | |
| CN100394969C (en) | Osteoporosis treating compound Chinese preparation and its preparing process | |
| CN101574498B (en) | Compound cornu cervi pantotrichum bone strengthening capsule for treating osteoporosis and method for quatitatively determining the quality thereof | |
| CN111617128A (en) | Traditional Chinese medicine compound composition with effect of promoting bone health and preparation method and application thereof | |
| CN1895504A (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN112891366B (en) | Traditional Chinese medicine active ingredient formula for treating postmenopausal osteoporosis and application thereof | |
| CN103316143A (en) | Chinese medicine composition for inhibiting rheumatoid arthritis inflammation and reducing bone mass loss and application thereof | |
| CN1589894A (en) | Medicinal composition for treating parafunctional metrorrhagia and its preparation method | |
| CN109601880A (en) | A kind of health food increasing bone density | |
| CN116966193B (en) | Medical application of cistanche glycoside F | |
| CN107137587A (en) | A kind of kidney-reinforcing drug of utilization animal kidney and preparation method thereof | |
| CN108310206B (en) | Traditional Chinese medicine composition for preventing or treating osteoporosis and preparation method and application thereof | |
| WO2022247640A1 (en) | Pharmaceutical composition for preventing or treating primary osteoporosis and preparation method therefor | |
| WO2021160104A1 (en) | Folium apocyni veneti extract, and preparation method therefor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |